Answers are grounded in this paper and cite their sources.
CD44ICD promotes breast cancer stemness via PFKFB4-mediated glycolysis, and therapies that target PFKFB4 (e.g., 5MPN therapy) may lead to improved outcomes for cancer patients.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: